Campuses

As France's leading biocluster, Genopole is an incubator for cutting-edge projects in biotechnology. Located in the city of Évry, just south of Paris, Genopole provides a unique environment for scientists and entrepreneurs seeking to advance research and innovation.

Discover >

Advantages

Genopole accompanies researchers, postdocs and start-up entrepreneurs through all the phases of their projects to ensure the best possible conditions for business development.

Discover >

Genopole’s citizens

Every day, at Genopole, researchers, entrepreneurs and students cross paths, share ideas and unite forces in a veritable melting pot for innovation.

Discover >

Highlights

Giving wings to research and empowering employment in our community are cornerstones of Genopole's mission. Catch up on recent scientific advances, the accomplishments of our biotech actors and the events that enliven the biocluster.

Discover >

Innovate with us

Discover >
Highlights

Seeing in high resolution at the Structural Biology Platform


With the support of Genopole & the University of Évry and to enrich its technological offer, the Structural Biology Platform has acquired the Opera Phenix Plus high content screening (HCS) system.
Manufactured by PerkinElmer, a pioneer in immersion lens technologies, the Opera Phenix Plus provides a two-fold increase in image resolution.
Visualization and quantification by MTBench technology of protein-protein interactions observed at Opera Phenix + in a cell line. Visualization and quantification by MTBench technology of protein-protein interactions observed at Opera Phenix + in a cell line.

The Évry shared-use Structural Biology Platform is a part of the Genopole-accredited Structure and Activity of Normal and Pathological Biomolecules Laboratory (SABNP: Inserm/University of Évry). In 2019, because of its recognized technologies and know-how in integrative structural biology, that platform was brought into the fold of the French Infrastructure for Integrated Structural Biology (FRISBI).
With the Opera Phenix Plus, the platform expands its possibilities for services and national & international partnerships.

Tens of thousands of high-resolution images in only a few hours

The Opera Phenix Plus HCS system can generate large quantities of images from biological samples in a matter of hours. Its high-resolution capacities enable the observation of defects in such cellular structures as the cytoskeleton, nucleoli, mitochondria, membrane proteins, neuron dendrites & axons and more. It can also be used for organoid studies or to observe fluorescent reporters for splicing, DNA repair, RNA translation and other cellular mechanisms of interest.
Furthermore, from the images it takes, the technology can produce exploitable quantitative data for high throughput drug screening. For example, the Opera Phenix Plus can produce 80,000 images in two hours for 150 pharmacological compounds.

HCS to energize MicroTubule bench

The HCS system will also provide impetus to MicroTubule bench (MTbench), another high-potential technology developed by SABNP and patented by Inserm Transfert. Producing as many as 63,000 images in only five hours, the Opera Phenix Plus greatly increases the number of images taken in a test run, thus greatly increasing in turn the reliability of this latter.

MTBench is a novel method for observing protein-protein and protein-RNA interactions, which are key phenomena in life sciences. The method detects and quantifies these phenomena in living cells via their naturally-present microtubule networks. MTBench will yield numerous applications, particularly for discovering and testing the actions of novel treatments and for expanding current knowledge on disease-associated cellular dysfunctions. For example, MTBench can be used in living cells to explore the impact of disease-causing mutations, better understand their underlying mechanisms and ultimately identify molecules able to counteract them.

CitationDavid Pastré, director of SABNP : «Thanks to the support of Genopole and the University of Évry, my lab was able to acquire an imaging technology combining high throughput and high resolution. The HCS system is vital to the development of our novel, patented technology for the analysis of biomolecular interactions, notably those involving RNA and proteins, in living cells. The equipment is mutualized and available to the entire public and private research community.»

How MTBench works
The microtubules (blue cylinders) are used as a support to capture and observe interaction phenomena. The “bait” protein (orange) is fused to a fluorescent reporter (red) and a microtubule binding domain. The “prey” protein (gray) is fused to another fluorescent reporter (green). Any interactions between bait and prey are visible and quantifiable via the fluorescence emitted along the microtubules.

How MTBench works
Interaction between bait and prey proteins on the microtubule surface underlying the MTBench technology.

HCS and MTBench: a duo to increase the attractiveness of the Structural Biology Platform

The complementarity of the high content screening system enables the large-scale and even industrial deployment of SABNP’s MTBench technology. In the setting of academic partnerships with other research labs, MTBench will be a part of the Structural Biology Platform’s service offer.

In the industrial setting, MTbench will be proposed by the Genopole company Synsight. With the stand-alone and MTBench-complementary advantages it brings, the Opera Phenix Plus system will make Synsight a major user of the Structural Biology Platform.

Illustration : Visualisation et quantification par la technologie MTBench des interactions protéines-protéines, observées à l’Opera Phenix+ dans une lignée cellulaire.

Visualisation et quantification par la technologie MTBench des interactions protéines-protéines, observées à l'Opera Phenix+ dans une lignée cellulaire.
La figure illustre un cas de forte interaction entre deux protéines, révélé par la fluorescence qui se concentre le long du réseau de microtubules.

Synsight is specialized in the discovery and design of novel therapeutic compounds for the pharmaceutical industry. The company’s activity is built upon a propriety and integrated platform that combines artificial intelligence (AI) and high content screening. Synsight proposes two complementary screening strategies: a phenotypic approach that evaluates therapeutic effect globally; and a therapeutic target-based approach that defines modes of action.

The first involves imaging analyses with deep-learning algorithms and will be made possible by the enormous amount of high-resolution images that Opera Phenix Plus will be able to produce (>50,000 daily). Synsight’s second approach involves biological targets, which the company seeks to modulate through high-throughput screening using the MTBench technology, for which it has exclusive commercial-use rights. Its approaches can be integrated within those of its clients, both for the identification (active compound identified by screening, called “hits”) and optimization (selection of high potential compounds, called “leads”) of drug candidates.

CitationCyril Bauvais, CEO of Synsight : «Synsight has an exclusive world license for the propriety cellular testing technology MTbench. When paired with extracellular biophysics tests, MTBench will provide multiparametric knowledge on molecular effects (within and without the cell) and enable artificial intelligence learning for the selection and design of efficacious compounds. In our opinion, the capacities of an AI can result only from the quality and robustness of the data underlying its learning. Quite simply, having access to such equipment is what will allow us to launch our offer.»

A scientific article there upon will soon be submitted in partnership with SABNP and the Institute of Natural Substances Chemistry (ICSN). Also, a cancer-associated interaction between two RNA binding proteins, YB-1 and Lin28, was recently published in Communications Biology (Nature) by Synsight, SABNP and Russian Academy of Sciences.

A unique platform in Europe


With the HCS Opera Phenix plus, the shared-use Structural Biology Platform gains a cutting-edge imaging technology. Associated with the novel MicroTubule bench method and under the team’s expert hand, the Opera Phenix plus will most notably create new possibilities for studies on protein-protein and protein-RNA interactions, which have great medical importance but suffer currently from a lack of technological means.

Pour aller plus loin

Access to the Structural Biology Platform

For more information on the platform, its technologies and the conditions for access to them, click here. Beyond the technologies discussed above, the Structural Biology Platform also provides access to a 600 MHz NMR spectrometer and two atomic force microscopes.

Article posted on 19 March 2021

Share
Highlights

Latest news


traitement des plaies diabétiques issu de peau et d’écailles de poissons

CERITD: Treating deep wounds with fish skin

CERITD and the South Île-de-France Medical Center are testing an innovative, natural fish-skin-based treatment for diabetic foot ulcers.

Discover
SYSFATE

Sysfate Team: A tool to digitize organs

Sysfate at Genoscope has combined image analysis and genomics to create MULTILAYER, a tool to digitize biological tissues and organs.

Discover
muscle fiber

Signs of myopathy detected before muscle formation

An I-Stem team has revealed very early embryonic molecular signs of Duchenne muscular dystrophy occurring upstream of muscle development itself

Discover
Neurons representation - Cells affected by CMT

Gene therapy for Charcot-Marie-Tooth disease makes headway

A gene therapy for Charcot-Marie-Tooth disease has been shown to be efficacious in an animal-model study cosigned by a research team created through Genopole support.

Discover
LAST - Makeup by Global Bioenergies

Global Bioenergies launches its makeup brand

Interview with Marc Delcourt, founder and CEO of Global Bioenergies, launches its makeup brand : LAST

Discover
NEB France celebrate 10 years @ Genopole

New England Biolabs France Celebrates 10 Years!

Its French affiliate arrived at Genopole in 2011 and to mark its 10th anniversary in France, the company invites you to participate in monthly activities to be held throughout 2021.

Discover
MSCA COFUND 2020 - ApogeeBio Laureate

COFUND-MSCA2020 : ApogeeBio chosen by the EC

Submitted by Genopole and its on-site partners, the ApogeeBio project for research grants has been selected by the European Commission for Marie Skłodowska-Curie Actions co-funding (MSCA-Cofund-2020).

Discover
Genhotel -  fibroblastes, cancer & Polyarthrite

Metabolic reprogramming involved in rheumatoid arthritis and cancer

The researchers from GenHotel (University of Évry-Paris Saclay, Genopole) have shed light on certain aspects common to rheumatoid arthritis and cancer.

Discover
AB Science L. Gros

Multiple sclerosis and COVID-19: promising results from AB Science

AB Science has been announcing a series of positive results concerning the efficacy of its product, masitinib, in such pathologies as multiple sclerosis, severe asthma resistant to oral steroids, COVID-19 and amyotrophic lateral sclerosis.

Discover
Placton - Tara Oceans

Bioinformatics and Tara Oceans

A team from the Genomics Metabolics Laboratory (Genoscope – CEA/CNRS/University of Évry) has developed a bioinformatics method for environmental genomics analyses able to identify species and associations of species.

Discover
Globules rouges - Avancées scientifiques

CRISPR-Cas9 for blood and metabolic diseases – Integrare

In an article published in Nature Communications, an Integrare team headed by Dr. Mario Amendola has described an innovative genome editing strategy aimed at modifying hematopoietic stem cells.

Discover
Généthon - Genopole's Laboratory

Treating more patients with gene therapies – Généthon

A Genethon team has successfully inhibited immune response to adeno-associated virus vectors, and in so doing, opened potential paths for treating more patients with gene therapies.

Discover
COVID-19 Disease Map

A single interactive map for all that is known on COVID-19

The objective for this latter is to build a sole referential comprising the totality of scientific knowledge on SARS-CoV-2/human-host interactions and thus contribute to the identification of therapeutic possibilities.

Discover
cellular membrane

Mapping membrane nanotubes – Lambe

A team from the Genopole-accredited Laboratory for Analysis and Modeling in Biology and the Environment (Lambe) has developed an experimental technique to study cell membrane nanotubes. These largely unknown structures play an essential role in cellular biomolecule transport.

Discover
Laboratory

Toward the industrialization of gene therapies -Polytheragene

Polytheragene is developing a polymer that will improve upon the current market standards for the production of viral particles for therapeutics. The polymer will be used by Genethon and Yposkesi to enhance the bioproduction of gene therapy vectors.

Discover
Jean Weissenbach

Jean Weissenbach: a portrait

Jean Weissenbach, a pioneer in France for the exploration of the human genome and a scientific icon at Genopole, talks about his career in an interview published 18 March 2020 in CNRS News.

Discover
cellular membrane

A nanopore to identify amino acids – Lambe

A team from the Laboratory for Analysis and Modeling in Biology and the Environment (Lambe – University of Évry/University of Cergy-Pontoise/CNRS) used a natural aerolysin nanopore to successfully identify 13 of the 20 amino acids that make up proteins.

Discover
Genopole - European projects

Green light from Europe for the Genopole-coordinated project GEN.ERA

Le projet européen GEN.ERA*, coordonné par Genopole, est sélectionné par la Commission européenne. Il vise à renforcer par une coopération entre clusters, l’internationalisation d’entreprises du secteur de la génomique au-delà du continent européen.

Discover
actus

New accomplishment in gene therapies

A clinical trial for a gene therapy to treat a severe immunodeficiency has provided highly promising initial results.

Discover
View all >
With support